Lupin which is the third largest drug maker by sales of the country, has posted a 21 percent increase in its net profit to Rs 633 crore for the third quarter ended December.

During the same period of previous year, the company had posted a profit of Rs 524.6 crores.

The revenues increased by 26 percent to Rs 4483 crore.

Company’s EBITDA margin has stood at 27.1 percent.

Read EquityPandit’s Technical Analysis on Nifty Pharma